Related Experiment Videos
The epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies
1Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.
Abstract:
The epidermal growth factor (EGF) receptor is a potential target for antitumor therapy, because it is expressed at high levels on many human tumor cells and appears to be involved in autocrine stimulation of cell growth in a number of experimental studies. Anti-EGF receptor monoclonal antibodies (MAbs) which block ligand binding can prevent the growth in culture of cells that are stimulated by EGF or TGF-alpha. Growth of human tumor xenografts bearing high levels of EGF receptors is also inhibited. A Phase I trial in patients with squamous cell carcinoma of the lung has demonstrated the capacity of a single dose of 120 mg anti-EGF receptor MAb to localize in such tumors and to achieve saturating concentrations in the blood for more than 3 days, without causing toxicity.
Insights
Monoclonal antibodies targeting the epidermal growth factor (EGF) receptor show promise for antitumor therapy. A Phase I trial confirmed these antibodies can reach tumors and remain in the blood for days without toxicity.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Epidermal Growth Factor (EGF) receptor is overexpressed in many human tumors.
- EGF receptor signaling promotes tumor cell growth and proliferation.
- Targeting EGF receptor is a potential strategy for cancer therapy.
Purpose of the Study:
- To evaluate the efficacy and safety of anti-EGF receptor monoclonal antibodies (MAbs) in preclinical models and a Phase I clinical trial.
- To assess the MAb's ability to inhibit tumor growth.
- To determine the pharmacokinetic profile and toxicity of the anti-EGF receptor MAb.
Main Methods:
- Preclinical studies using cell cultures and human tumor xenografts.
- Phase I clinical trial in patients with squamous cell carcinoma of the lung.
- Administration of a single dose of 120 mg anti-EGF receptor MAb.
- Assessment of MAb localization in tumors and blood concentrations.
- Evaluation of treatment toxicity.
Main Results:
- Anti-EGF receptor MAbs inhibited the growth of EGF-stimulated cells in vitro.
- Tumor xenograft growth was inhibited in vivo.
- The MAb successfully localized in tumors and achieved saturating blood concentrations for over 3 days.
- No toxicity was observed in the Phase I trial.
Conclusions:
- Anti-EGF receptor monoclonal antibodies are a viable therapeutic option for tumors overexpressing the EGF receptor.
- The MAb demonstrated favorable pharmacokinetics and safety profile in early clinical evaluation.
- Further clinical trials are warranted to explore the therapeutic potential of anti-EGF receptor MAbs in cancer treatment.